Are US Patients Really Subsidising Healthcare In Switzerland?
I report on the Swiss pharmaceutical industry and healthcare topics such as access to medicine, biomedical innovation, and the impact of diseases like cancer. I grew up just outside San Francisco and studied international affairs with a focus on development economics and healthcare policy. Prior to joining SWI swissinfo in 2018, I was a freelance journalist and a researcher on business and human rights.
-
More from this auth
English Departme
My work focuses on engaging with you, our audience, and strengthening trust in our journalism. I develop engagement tools such as multilingual debates and help distribute our content to users across platforms. A former nurse, I later pursued English linguistics and media studies where I developed a keen interest in journalism and news in the digital age.
-
More from this auth
English Departme
US President Donald Trump argues US patients pay high prices for medicine so pharmaceutical companies can invest in new treatments that benefit the whole world. As Trump sees it, US patients are subsidising healthcare in other countries.
There is some truth to this.
Are US drug prices really that high?The US makes up just 4.2% of the world's population but delivers 40% to 60% of total revenue for big pharma companies – including Swiss companies Roche and Novartis. Last year, just over half of Roche's global pharmaceutical revenue (CHF46 billion, $57 billion) came from the US.
This is because companies sell more medicine in the US and charge more. Multiple studies, including this oneExternal link from the Rand corporation, an American think tank, show prices of brand-name prescription drugs are two to three times more in the US than in Europe.
However, Switzerland still has some of the highest drug prices and per capita healthcare costs in Europe.
Why are US drug prices so high?Unlike in Switzerland or most of Europe, there are no government price controls or a central price negotiator. The Inflation Reduction Act, enacted in 2022, authorised the US government to negotiate directly with drug companies on some drugs for the state-run insurance scheme for seniors (Medicare). But this is only for a small set of drugs and patients.
In May, Trump announced the“most-favoured nation” executiveExternal link order, which intends to tie US drug prices to those paid by other developed countries. This would bring down drug prices in the US by 60% to 90%, according to Trump. He also called on European governments to raise prices to make up for any loss in revenue.
He restated his demands this summer. Trump sent letters to 17 major pharmaceutical companies calling for immediate measures to lower drug prices in the US.
More More Medicine access Despite Trump's bold claims, medicine prices in Europe won't rise anytime soonThis content was published on May 15, 2025 US President Trump has taken aim at Europe for undercharging for medicine. But raising prices in Europe would face strong pushback.
Read more: Despite Trump's bold claims, medicine prices in Europe won't rise anytime soo What happens if prices drop in the US?The ten largest pharmaceutical companies spend around 20% of their global revenue on new treatments. If prices drop in the US (and nothing else changes) companies will have less revenue, which could lead to less investment in new medicine.
But there remains a big question: how much profit companies make on high US prices.
Edited by Veronica DeVore/Virginie Mangin/ts
More Debate Hosted by: Jessica Davis Plüss What's your experience with rising costs for healthcare and medicine?What do you think should be done to make medicine more accessible? How has this impacted you?
Join the discussi Jan 31, 2023 112 Comments View the discussi
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research

- Chaingpt Pad Unveils Buzz System: Turning Social Hype Into Token Allocation
- Global Luxury Furniture Market Edition 2025: Industry Size To Reach USD 36.56 Billion By 2033, CAGR Of 4.06%.
- Japan Buy Now Pay Later Market Size To Surpass USD 145.5 Billion By 2033 CAGR Of 22.23%
- Bitmex And Tradingview Announce Trading Campaign, Offering 100,000 USDT In Rewards And More
- Excellion Finance Scales Market-Neutral Defi Strategies With Fordefi's MPC Wallet
- From Zero To Crypto Hero In 25 Minutes: Changelly Introduces A Free Gamified Crash Course
Comments
No comment